What question did this study set out to answer?

This research aims to evaluate healthcare resource utilization following CAR T-cell therapy at newly authorized treatment centers in the US.

December 8, 2025Blood

Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis assesses healthcare resource utilization in CAR T-cell therapy patients at new centers, suggesting manageable outcomes.

This research aims to evaluate healthcare resource utilization following CAR T-cell therapy at newly authorized treatment centers in the US.
Retrospective observational study using open claims data from HealthVerity Marketplace
Included adults with inpatient CAR T-cell infusion at new treatment centers authorized from 2023 onward
Key outcomes included hospitalization length of stay, ICU admissions, and 30-day readmission rates analyzed via descriptive statistics
Total of 43 patients received CAR T-cell therapy across 4 new treatment centers
Mean hospitalization length of stay was 18 days for non-MM patients and 11 days for MM patients
30-day readmission rates observed in <18% for non-MM and <15% for MM patients, with no ICU admissions reported

Oluwole et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis assesses healthcare resource utilization in CAR T-cell therapy patients at new centers, suggesting manageable outcomes.